Study population
| Characteristic . | Total genotyped (N = 656) . | HSCT eligible (N = 545) . | ||
|---|---|---|---|---|
| N or median . | Percentage or range . | N or median . | Percentage or range . | |
| Age, y | 46 | 18-60 | 46 | 18-60 |
| Sex | ||||
| Male | 351 | 53.5 | 285 | 52.3 |
| Female | 305 | 46.5 | 260 | 47.7 |
| ECOG PS | ||||
| 0 | 284 | 43.3 | 233 | 42.8 |
| 1 | 298 | 45.5 | 250 | 45.9 |
| 2-3 | 66 | 10 | 56 | 10.2 |
| NA | 8 | 1.2 | 6 | 1.1 |
| WBC, 109/L | 8.4 | 0.3-377.4 | 8.7 | 0.3-377.4 |
| ELN 2017 risk | ||||
| Favorable | 231 | 35.2 | 219 | 40.2 |
| Intermediate | 194 | 29.6 | 166 | 30.4 |
| Adverse | 222 | 33.8 | 160 | 29.4 |
| Missing | 9 | 1.4 | 0 | 0 |
| Characteristic . | Total genotyped (N = 656) . | HSCT eligible (N = 545) . | ||
|---|---|---|---|---|
| N or median . | Percentage or range . | N or median . | Percentage or range . | |
| Age, y | 46 | 18-60 | 46 | 18-60 |
| Sex | ||||
| Male | 351 | 53.5 | 285 | 52.3 |
| Female | 305 | 46.5 | 260 | 47.7 |
| ECOG PS | ||||
| 0 | 284 | 43.3 | 233 | 42.8 |
| 1 | 298 | 45.5 | 250 | 45.9 |
| 2-3 | 66 | 10 | 56 | 10.2 |
| NA | 8 | 1.2 | 6 | 1.1 |
| WBC, 109/L | 8.4 | 0.3-377.4 | 8.7 | 0.3-377.4 |
| ELN 2017 risk | ||||
| Favorable | 231 | 35.2 | 219 | 40.2 |
| Intermediate | 194 | 29.6 | 166 | 30.4 |
| Adverse | 222 | 33.8 | 160 | 29.4 |
| Missing | 9 | 1.4 | 0 | 0 |
ECOG, Eastern Cooperative Oncology Group; NA, not available; PS, performance status.